Hemoglobin targets for the anemia of chronic kidney disease: A meta-analysis of randomized, controlled trials

Journal of the American Society of Nephrology

Volumn 15, Issue 12, 2004, Pages 3154-3165

  Strippoli, Giovanni P M ^a,b   Craig, Jonathan C ^a,b   Manno, Carlo ^a   Schena, Francesco P ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; ERYTHROPOIETIN; HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLACEBO;

ANEMIA; ARTICLE; BLOOD TRANSFUSION; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; HYPERKALEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; META ANALYSIS; MORTALITY; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SEIZURE; STROKE; SURVIVAL; SYSTEMATIC REVIEW; THROMBOSIS;

EID: 9644283016     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ASN.0000145436.09176.A7     Document Type: Article

References (59)

1. Hsu CY, McCulloch CE, Curhan GC: Epidemiology of anemia associated with chronic renal insufficiency among adults in the United States: Results from the Third National Health and Nutrition Examination Survey. J Am Soc Nephrol 13: 504-510, 2002
2. Obrador GT, Roberts T, St Peter WL, Frazier E, Pereira BJ, Collins AJ: Trends in anemia at initiation of dialysis in the United States. Kidney Int 60: 1875-1884, 2001
3. Hemodialysis. Australia and New Zealand Registry Annual Report 2001. Available: http://www.anzdata.org/au
4. Caro J, Brown S, Miller O, Murray T, Erslev AJ: Erythropoietin levels in uremic nephric and anephric patients. J Lab Clin Med 93: 449-458, 1979
5. Klang B, Bjorvell H, Clyne N: Quality of life in predialytic uremic patients. Qual Life Res 5: 109-116, 1996
6. Mann JF: What are the short-term and long-term consequences of anaemia in CRF patients? Nephrol Dial Transplant 14[Suppl 2]: 29-36, 1999
7. Humphries JE: Anemia of renal failure. Use of erythropoietin. Med Clin North Am 76: 711-725, 1992
8. Valderrabano F, Jofre R, Lopez-Gomez JM: Quality of life in end-stage renal disease patients. Am J Kidney Dis 38: 443-464, 2001
9. Sundal E, Kaeser U: Correction of anaemia of chronic renal failure with recombinant human erythropoietin: Safety and efficacy of one year's treatment in a European multicentre study of 150 haemodialysis-dependent patients. Nephrol Dial Transplant 4: 979-987, 1989
10. McMahon LP, Mason K, Skinner SL, Burge CM, Grigg LE, Becker GJ: Effects of haemoglobin normalization on quality of life and cardiovascular parameters in end-stage renal failure. Nephrol Dial Transplant 15: 1425-1430, 2000
11. Nissenson AR: Novel erythropoiesis stimulating protein for managing the anemia of chronic kidney disease. Am J Kidney Dis 38: 1390-1397, 2001
12. Sikole A, Stojanovic A, Polenakovic M, Petrusevska G, Sadikario S, Saso R, Jovanovski M: How erythropoietin affects bone marrow of uremic patients. Am J Nephrol 17: 128-136, 1997
13. Keown PA: Quality of life in end-stage renal disease patients during recombinant human erythropoietin therapy. The Canadian Erythropoietin Study Group. Contrib Nephrol 88: 81-86, 1991
14. Hays RD, Kallich JD, Mapes DL, Coons SJ, Carter WB: Development of the Kidney Disease Quality of Life (KDQOL) instrument. Qual Life Res 3: 329-338, 1994
15. Laupacis A: A randomized double-blind study of recombinant human erythropoietin in anaemic hemodialysis patients. Canadian Erythropoietin Study Group. Transplant Proc 23: 1825-1826, 1991
16. Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, Schwab SJ, Goodkin DA: The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 339: 584-590, 1998
17. Muirhead N: Erythropoietin is a cause of access thrombosis. Semin Dial 6: 184-188, 1993
18. Tonelli M, Winkelmayer WC, Jindal KK, Owen WF, Manns BJ: The cost-effectiveness of maintaining higher hemoglobin targets with erythropoietin in hemodialysis patients. Kidney Int 64: 295-304, 2003
19. Epoetin: For better or for worse? Lancet Oncol 5: 1, 2004
20. Crowther CA, Henderson-Smart DJ: Phenobarbital prior to preterm birth for preventing neonatal periventricular haemorrhage. Cochrane Database Syst Rev (3): CD000164, 2003
21. Schulz KF, Chalmers I, Hayes RJ, Altman DG: Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 273: 408-412, 1995
22. DerSimonian R, Laird N: Meta-analysis in clinical trials. Control Clin Trials 7: 177-188, 1986
23. Abraham PA, Macres MG: Blood pressure in hemodialysis patients during amelioration of anemia with erythropoietin. J Am Soc Nephrol 2: 927-936, 1991
24. Bahlmann J, Schoter KH, Scigalla P, Gurland HJ, Hilfenhaus M, Koch KM, Muthny FA, Neumayer HH, Pommer W, Quelhorst E: Morbidity and mortality in hemodialysis patients with and without erythropoietin treatment: A controlled study. Contrib Nephrol 88: 90-106, 1991
25. Berns JS, Rudnick MR, Cohen RM, Bower JD, Wood BC: Effects of normal hematocrit on ambulatory blood pressure in epoetin-treated hemodialysis patients with cardiac disease. Kidney Int 56: 253-260, 1999
26. Brandt JR, Avner ED, Hickman RO, Watkins SL: Safety and efficacy of erythropoietin in children with chronic renal failure. Pediatr Nephrol 13: 143-147, 1999
27. Clyne N, Jogestrand T: Effect of erythropoietin treatment on physical exercise capacity and on renal function in predialytic uremic patients. Nephron 60: 390-396, 1992
28. Conlon PJ, Kovalik E, Schumm D, Minda S, Schwab SJ: Normalization of hematocrit in hemodialysis patients with cardiac disease does not increase blood pressure. Ren Fail 22: 435-444, 2000
29. Foley RN, Parfrey PS, Morgan J, Barre PE, Campbell P, Cartier P, Coyle D, Fine A, Handa P, Kingma I, Lau CY, Levin A, Mendelssohn D, Muirhead N, Murphy B, Plante RK, Posen G, Wells GA: Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy. Kidney Int 58: 1325-1335, 2000
30. Kleinman KS, Schweitzer SU, Perdue ST, Bleifer KH, Abels RI: The use of recombinant human erythropoietin in the correction of anemia in predialysis patients and its effect on renal function: A double-blind, placebo-controlled trial. Am J Kidney Dis 14: 486-495, 1989
31. Kuriyama S, Tomonari H, Yoshida H, Hashimoto T, Kawaguchi Y, Sakai O: Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in nondiabetic patients. Nephron 77: 176-185, 1997
32. Lim VS, DeGowin RL, Zavala D, Kirchner PT, Abels R, Perry P, Fangman J: Recombinant human erythropoietin treatment in pre-dialysis patients. A double-blind placebo-controlled trial. Ann Intern Med 110: 108-114, 1989
33. Morris KP, Sharp J, Watson S, Coulthard MG: Non-cardiac benefits of human recombinant erythropoietin in end stage renal failure and anaemia. Arch Dis Child 69: 580-586, 1993
34. Revicki DA, Brown RE, Feeny DH, Henry D, Teehan BP, Rudnick MR, Benz RL: Health-related quality of life associated with recombinant human erythropoietin therapy for predialysis chronic renal disease patients. Am J Kidney Dis 25: 548-554, 1995
35. Sikole A, Polenakovic M, Spirovska V, Polenakovic B, Masin G: Analysis of heart morphology and function following erythropoietin treatment of anemic dialysis patients. Artif Organs 17: 977-984, 1993
36. Teehan BP, Benz RL, Sigler MH, Brown JM: Early intervention with recombinant human erythropoietin therapy. Semin Nephrol 10: 28-34, 1990
37. Watson AJ, Gimenez LF, Cotton S, Walser M, Spivak JL: Treatment of the anemia of chronic renal failure with subcutaneous recombinant human erythropoietin. Am J Med 89: 432-435, 1990
38. Effect of recombinant human erythropoietin therapy on blood pressure in hemodialysis patients. Canadian Erythropoietin Study Group. Am J Nephrol 11: 23-26, 1991
39. Conlon PJ, Kovalik E, Schumm D, Minda S, Schwab SJ: Normalization of hematocrit in hemodialysis patients does not affect silent ischemia. Ren Fail 22: 205-211, 2000
40. Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. Canadian Erythropoietin Study Group. BMJ 300: 573-578, 1990
41. Roth D, Smith RD, Schulman G, Steinman TI, Hatch FE, Rudnick MR, Sloand JA, Freedman BI, Williams WW Jr, Shadur CA: Effects of recombinant human erythropoietin on renal function in chronic renal failure predialysis patients. Am J Kidney Dis 24: 777-784, 1994
42. Furuland H, Linde T, Ahlmen J, Christensson A, Strombom U, Danielson BG: A randomized controlled trial of haemoglobin normalization with epoetin alfa in pre-dialysis and dialysis patients. Nephrol Dial Transplant 18: 353-361, 2003
43. Roger SD, McMahon LP, Clarkson A, Disney A, Harris D, Hawley C, Healy H, Kerr P, Lynn K, Parnham A, Pascoe R, Voss D, Walker R, Levin A: Effects of early and late intervention with epoetin alpha on left ventricular mass among patients with chronic kidney disease (stage 3 or 4): Results of a randomized clinical trial. J Am Soc Nephrol 15: 148-156, 2004
44. Jacobs C: Normalization of haemoglobin: Why not? Nephrol Dial Transplant 14[Suppl 2]: 75-79, 1999
45. Foley RN: Should hemoglobin be normalized in uremic patients? Clin Nephrol 58[Suppl 1]: S58-S61, 2002
46. Ritz E, Schwenger V: The optimal target hemoglobin. Semin Nephrol 20: 382-386, 2000
47. Ioannidis JP, Lau J: Heterogeneity of the baseline risk within patient populations of clinical trials: A proposed evaluation algorithm. Am J Epidemiol 148: 1117-1126, 1998
48. Chong ZZ, Kang JQ, Maiese K: Hematopoietic factor erythropoietin fosters neuroprotection through novel signal transduction cascades. J Cereb Blood Flow Metab 22: 503-514, 2002
49. Taylor JE, Henderson IS, Stewart WK, Belch JJ: Erythropoietin and spontaneous platelet aggregation in haemodialysis patients. Lancer 338: 1361-1362, 1991
50. Leyland-Jones B, BEST Investigators and Study Group: Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol 4: 459-460, 2003
51. Henke M, Laszig R, Rube C, Schafer U, Haase KD, Schilcher B, Mose S, Beer KT, Burger U, Dougherty C, Frommhold H: Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: Randomised, double-blind, placebo-controlled trial. Lancet 362: 1255-1260, 2003
52. Lohr KN, Aaronson NK, Alonso J, Burnam MA, Patrick DL, Perrin EB, Roberts JS: Evaluating quality-of-life and health status instruments: Development of scientific review criteria. Clin Ther 18: 979-992, 1996
53. Cody J, Daly C, Campbell M, Donaldson C, Grant A, Khan I, Vale L, Wallace S, MacLeod A: Frequency of administration of recombinant human erythropoietin for anaemia of end-stage renal disease in dialysis patients. Cochrane Database Syst Rev CD003895, 2002
54. Strippoli GF, Manno C, Schena FP, Craig JC: Haemoglobin and haematocrit targets for the anaemia of chronic renal disease. Cochrane Database Syst Rev (4): CD003967, 2003
55. Flamm CR, Aronson N, Bohn R: Use of Epoetin for Anemia in Chronic Renal Failure. Evidence Report/Technology Assessment N9.29, Rockville, MD, Agency for Healthcare Research and Quality, 2001 (Prepared by the Blue Cross and Blue Shield Association Technology Evaluation Center under contract No. 290-97-0015; AHRQ Publication No. 01-3016)
56. Collins AJ, Ma JZ, Xia A, Ebben J: Trends in anemia treatment with erythropoietin usage and patient outcomes. Am J Kidney Dis 32: S133-S141, 1998
57. Sackett DL: Bias in analytic research. J Chronic Dis 32: 51-63, 1979
58. Paniagua R, Amato D, Vonesh E, Correa-Rotter R, Ramos A, Moran J, Mujais S, Mexican Nephrology Collaborative Study Group: Effects of increased peritoneal clearances on mortality rates in peritoneal dialysis: ADEMEX, a prospective, randomized, controlled trial. J Am Soc Nephrol 13: 1307-1320, 2002
59. Depner T, Beck G, Daugirdas J, Kusek J, Eknoyan G: Lessons from the Hemodialysis (HEMO) Study: An improved measure of the actual hemodialysis dose. Am J Kidney Dis 33: 142-149, 1999